CN Patent

CN111440798A — 用于调节sod-1表达的组合物

Assigned to Biogen MA Inc · Expires 2020-07-24 · 6y expired

What this patent protects

本文公开了用于降低SOD‑1 mRNA和蛋白质表达的反义化合物和方法。此类方法、化合物和组合物适用于治疗、预防或改善SOD‑1相关疾病、病症和病状。此类SOD‑1相关的疾病包括肌萎缩性硬化(ALS)。

USPTO Abstract

本文公开了用于降低SOD‑1 mRNA和蛋白质表达的反义化合物和方法。此类方法、化合物和组合物适用于治疗、预防或改善SOD‑1相关疾病、病症和病状。此类SOD‑1相关的疾病包括肌萎缩性硬化(ALS)。

Drugs covered by this patent

Patent Metadata

Patent number
CN111440798A
Jurisdiction
CN
Classification
—
Expires
2020-07-24
Drug substance claim
No
Drug product claim
No
Assignee
Biogen MA Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.